

PHARMACEUTICAL 2023

## Jazz Pharmaceuticals plc Rank 19 of 446









PHARMACEUTICAL 2023



RealRate

Jazz Pharmaceuticals plc Rank 19 of 446

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 236% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,606,140
Cost of Goods Sold	0
Intangible Assets	7,487,099
Liabilities, Current	933,193
Liabilities, Non-Current	0
Other Assets	742,016
Other Compr. Net Income	-725,149
Other Expenses	1,114,689
Other Liabilities	0
Other Net Income	-317,177
Other Revenues	3,659,374
Property and Equipment	0
Research and Development	1,034,601
Selling, General and Administrative Expense	1,416,967

Output Variable	Value in 1000 USD
Assets	10,835,255
Liabilities	933,193
Expenses	3,566,257
Revenues	3,659,374
Stockholders Equity	9,902,062
Net Income	-224,060
Comprehensive Net Income	-586,634
Economic Capital Ratio	279%

